Side Effects of Valsartan, Losartan, Similar Blood Pressure Drugs Do Not Increase Coronavirus Risk: Study

While recent reports have suggested that side effects of blood pressure drugs like valsartan, losartan and other similar treatments may worsen COVID-19 infections, the findings of a new study indicates there does not appear to be any association between use of the medications and an increased risk of testing positive for coronavirus or suffering worse symptoms.

In March, a group of Swiss researchers published a letter in The Lancet Respiratory Medicine, warning that the novel coronavirus uses the angiotensin-converting enzyme 2 (ACE2) to bind to their targets, meaning ACE inhibitors or angiontensin II type-1 receptor blockers (ARBs) may increase the severity and lethality of the illness. This included drugs like valsartan, Benicar, Cozaar and similar blood pressure medications.

This led to concerns about whether the drugs should be taken during the ongoing global pandemic. However, according to a study published in the New England Journal of Medicine on May 1, researchers with the New York University Grossman School of Medicine say they found no connection between any of the five different categories of hypertensive medication and increased COVID-19 adverse health effects

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Researchers looked at data on nearly 12,600 patients tested for COVID-19, a little under half of whom tested positive. The researchers compared outcomes in patients who had been treated with the medications and those who had not.

Overall, about 17% of the patients suffered severe COVID-19 health effects. Of those taking the hypertension drugs, about 24% suffered severe symptoms. However, the researchers said the difference, less than 10%, was not statistically significant.

According to the findings, there was no association between the medications and the increased risk of a positive test or increased severity of the illness.

“We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications,” the researchers concluded.

There are currently more than 1.1 million confirmed cases in the U.S., and more than 60,000 deaths as of May 4, according to various sources .

The FDA and the CDC, along with drug manufacturers, are continuing to work on expanding available healthcare facility COVID-19 test kits, while closely monitoring the spread of cases across the nation.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.